Martin Achleitner
Dresden, SN, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Successful rescue therapy with the anti-CD19 antibody tafasitamab in anti-MDA5-positive interstitial lung disease suggests therapeutic effects of conventional anti-CD19 antibodies.
Journal: Annals of the rheumatic diseases
Published: May 29, 2026
Interleukin-6 receptor blockade leads to low fibrinogen values as part of their effects on the acute phase.
Journal: Rheumatology (Oxford, England)
Published: March 29, 2025
Absence of Type I Interferon Autoantibodies or Significant Interferon Signature Alterations in Adults With Post-COVID-19 Syndrome.
Journal: Open forum infectious diseases
Published: September 19, 2023
Clinical improvement of Long-COVID is associated with reduction in autoantibodies, lipids, and inflammation following therapeutic apheresis.
Journal: Molecular psychiatry
Published: February 20, 2023
Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19.
Journal: The Lancet. Microbe
Published: April 05, 2021
Chronic post-COVID-19 syndrome and chronic fatigue syndrome: Is there a role for extracorporeal apheresis?
Journal: Molecular psychiatry
Published: February 19, 2021
Lack of Trex1 Causes Systemic Autoimmunity despite the Presence of Antiretroviral Drugs.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: May 15, 2017
Loss of Trex1 in Dendritic Cells Is Sufficient To Trigger Systemic Autoimmunity.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: April 27, 2016
Deregulated type I IFN response in TREX1-associated familial chilblain lupus.
Journal: The Journal of investigative dermatology
Published: November 26, 2013
Mammalian RNase H2 removes ribonucleotides from DNA to maintain genome integrity.
Journal: The Journal of experimental medicine
Published: July 18, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026